Amarin Corporation plc announced that its REDUCE-IT cardiovascular outcomes study has reported and documented more than 90% of the targeted 1,612 primary major adverse cardiovascular events (MACE). The vast majority of these events have been confirmed (i.e., positively adjudicated as a patient’s first on-study primary event) with some unable to be fully adjudicated per study protocol until after completion of the associated patients’ final study visits. For this first of its kind, potentially landmark, REDUCE-IT cardiovascular outcomes study, Amarin confirmed that it is on track for onset of the targeted 1,612th event to occur before the end of First Quarter 2018. Patients are being scheduled for final study visits commencing March 1, 2018. Amarin maintains its guidance to report top-line results from the study before the end of Third Quarter 2018.